HR 4565
114th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Marketing and advertising
Prescription drugs
Responsibility in Drug Advertising Act of 2016
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 19, 2016
Referred to the Subcommittee on Health.
Feb 12, 2016
Referred to the House Committee on Energy and Commerce.
Feb 12, 2016
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Responsibility in Drug Advertising Act of 2016
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.
What's happening now
Referred to the Subcommittee on Health.
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cite this page
U.S. Congress. (2026). H.R. 4565: Responsibility in Drug Advertising Act of 2016. 114th Congress. Open America. https://openamerica.io/bill/114-HR-4565/
"H.R. 4565: Responsibility in Drug Advertising Act of 2016." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-4565/.
H.R. 4565, 114th Cong. (2026), https://openamerica.io/bill/114-HR-4565/.
[H.R. 4565: Responsibility in Drug Advertising Act of 2016](https://openamerica.io/bill/114-HR-4565/)